BioVaxys Technology Business Summary

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company that generates revenue through a hybrid model of out-licensing its proprietary technology, establishing research collaborations, and securing future royalty streams, with its first royalty income anticipated in 2026. The company operates across three primary business segments: oncology, focusing on its DPX-based maveropepimut-S (MVP-S) and HapTenix tumor cell vaccines for bladder, ovarian, and breast cancers; infectious diseases, including vaccine candidates for RSV, influenza, and rabies; and antigen desensitization for food allergies, such as its DPX-rPA peanut allergy program. BioVaxys competes directly with immunotherapy and vaccine platform leaders like Moderna, BioNTech, and BeiGene, distinguishing itself through its DPX "no release" delivery mechanism, which offers superior stability and sustained T-cell activation compared to traditional lipid nanoparticle (LNP) delivery systems. The company was founded by a veteran team including CEO James Passin, a former hedge fund manager with 20 years of experience in biotech financing; President and COO Kenneth Kovan, who brings over 30 years of biopharmaceutical commercial development expertise from firms like GSK and Wyeth; and CMO David Berd, MD, a pioneer in cancer immunotherapy and inventor of the MVax and OVax platforms. The leadership team is supported by CFO Christopher Cherry, who was appointed in April 2024 to oversee financial strategy. Notable board members and advisors include Dr. James Tartaglia, the former Global Head of Vaccine Development at Sanofi, and Scientific Advisor Dr. Marianne Stanford, the former VP of R&D at IMV Inc. and a leading expert on the DPX platform.